|
Cellular and Genetic DiscoveryToward Curative Therapy in Myeloproliferative Disorders (MPD)
RFA HL-04-034
Letter of Intent Receipt Date: Jan. 16, 2005
Application Receipt Date: Feb. 16, 2005
This RFA solicits applications for research to identify new cellular and genetic markers associated with the origin and progression of myeloproliferative
disorders (MPD) that can be applied to the future development of novel therapeutics with curative intent. MPDs represent a broad range of clinical entities, which creates difficulties in prompt assignment of diagnosis, prediction of prognosis, characterization of disease evolution,
and research on the etiology and progression of disease.
This RFA will use the R01 award mechanism.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2101
Inquiries: Dr. R. Allan Mufson, am214t@nih.gov
Reducing Barriers to Symptom Management and Palliative Care
RFA-CA-05-013
Letter of Intent Receipt Date: Aug. 24, 2004
Application Receipt Date: Sept. 24, 2004
This RFA is to solicit applications for research directed at developing and testing interventions to reduce or overcome barriers to the delivery of appropriate symptom management
and palliative care for persons living with cancer, thereby decreasing
suffering and improving health and quality of life. Relative research should: 1) generate knowledge about how to reduce barriers to delivery of symptom management and palliative
care, 2) address barriers for vulnerable, medically underserved, and special populations to access and receive palliative care, and 3) encourage
research collaborations across disciplines.
This RFA will use NIH R01 (research project grant) and R21 (exploratory/developmental grant) award mechanisms.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2100
Inquiries: Dr. Ann O'Mara, omaraa@mail.nih.gov
|
